WO2026085406A1 - Thérapies combinées pour la perte de poids et le maintien du poids - Google Patents

Thérapies combinées pour la perte de poids et le maintien du poids

Info

Publication number
WO2026085406A1
WO2026085406A1 PCT/US2025/051405 US2025051405W WO2026085406A1 WO 2026085406 A1 WO2026085406 A1 WO 2026085406A1 US 2025051405 W US2025051405 W US 2025051405W WO 2026085406 A1 WO2026085406 A1 WO 2026085406A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
pharmaceutically acceptable
acceptable salt
weekly dose
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/051405
Other languages
English (en)
Inventor
Charlotte E. HINDS
James S. MINNION
Gregory A. Gaich
Brian K. Hubbard
Lisa C. BURNETT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zihipp Ltd
Original Assignee
Zihipp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zihipp Ltd filed Critical Zihipp Ltd
Publication of WO2026085406A1 publication Critical patent/WO2026085406A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente divulgation concerne des combinaisons pour réduire le poids et/ou prévenir la prise de poids chez un sujet (par exemple, un sujet obèse), comprenant un analogue de l'amyline et un agoniste du récepteur du GLP-1. Comme décrit dans l'invention, l'agoniste du récepteur du GLP-1 et l'analogue de l'amyline peuvent être administrés à un sujet dans la même composition pharmaceutique ou dans des compositions pharmaceutiques séparées (par exemple, par administration simultanée ou ultérieure).
PCT/US2025/051405 2024-10-18 2025-10-17 Thérapies combinées pour la perte de poids et le maintien du poids Pending WO2026085406A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202463709370P 2024-10-18 2024-10-18
US63/709,370 2024-10-18
US202463737066P 2024-12-20 2024-12-20
US63/737,066 2024-12-20

Publications (1)

Publication Number Publication Date
WO2026085406A1 true WO2026085406A1 (fr) 2026-04-23

Family

ID=97916330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/051405 Pending WO2026085406A1 (fr) 2024-10-18 2025-10-17 Thérapies combinées pour la perte de poids et le maintien du poids

Country Status (1)

Country Link
WO (1) WO2026085406A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022123271A1 (fr) 2020-12-11 2022-06-16 Imperial College Innovations Limited Nouveaux composés
WO2024110763A1 (fr) 2022-11-24 2024-05-30 Ip2Ipo Innovations Limited Analogues d'amyline

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022123271A1 (fr) 2020-12-11 2022-06-16 Imperial College Innovations Limited Nouveaux composés
WO2024110763A1 (fr) 2022-11-24 2024-05-30 Ip2Ipo Innovations Limited Analogues d'amyline

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERGE ET AL.: "describe pharmaceutically acceptable salts in detail in", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
FRIAS JUAN P ET AL: "Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial", THE LANCET, vol. 402, no. 10403, 1 August 2023 (2023-08-01), AMSTERDAM, NL, pages 720 - 730, XP093356150, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(23)01163-7 *
KRUSE THOMAS ET AL: "Development of Cagrilintide, a Long-Acting Amylin Analogue", JOURNAL OF MEDICINAL CHEMISTRY, vol. 64, no. 15, 21 July 2021 (2021-07-21), US, pages 11183 - 11194, XP093116492, ISSN: 0022-2623, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00565> DOI: 10.1021/acs.jmedchem.1c00565 *
MATHIESEN ET AL.: "Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat.", FRONT ENDOCRINOL (LAUSANNE, vol. 11, 8 January 2021 (2021-01-08), pages 617400

Similar Documents

Publication Publication Date Title
JP7541600B2 (ja) Ｇｉｐアゴニスト化合物及び方法
AU2018202504B2 (en) Use of long-acting GLP-1 peptides
US8642548B2 (en) Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
AU2011348202A9 (en) Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides
AU2004241242A1 (en) Compositions for delivering peptide YY and PYY agonists
CA3073011C (fr) Analogue peptidique d&#39;oxyntomoduline acylee
US20240216476A1 (en) Combination of bitter receptor agonist and gut-signaling compound
AU2016324119B2 (en) Long-acting adrenomedullin derivative
BR112020021562A2 (pt) conjugados de peptídeo tirosina tirosina cíclico acoplado ao peptídeo de fusão semelhante ao peptídeo glucagon-1 (glp-1) e usos dos mesmos
CA3222051A1 (fr) Derive polypeptidique ayant un effet d&#39;activation a double cible de glp-1r et de gipr, procede de preparation associe et son utilisation
US20210315908A1 (en) Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
AU2022413318A1 (en) Effective doses of cnp conjugates
ES2980806T3 (es) Combinación de análogos de la somatostatina con inhibidores de la 11-beta-hidroxilasa
WO2026085406A1 (fr) Thérapies combinées pour la perte de poids et le maintien du poids
US20260115298A1 (en) PTH Treatment Regimen Comprising Two PTH Compounds
Johns and et al. Future Antidiabetic Drugs
CA3166027A1 (fr) Co-agonistes du glucagon et du glp-1 pour le traitement d&#39;une maladie renale chronique et d&#39;une maladie renale diabetique dans le diabete de type 2
WO2025178928A1 (fr) Polythérapie pour traiter l&#39;obésité
WO2024234320A1 (fr) Dérivé de peptide-1 de type glucagon à action prolongée, son procédé de préparation et son utilisation
EP4731619A2 (fr) Nouveau co-médicament, co-administration et administration séquentielle d&#39;un ligand rbp4/ttr bispécifique et de rétinol c20-d3 à des fins d&#39;élimination d&#39;effets indésirables oculaires basés sur un mécanisme dans le traitement de la dégénérescence maculaire et de l&#39;amyloïdose ttr
HK40101394A (zh) 酰化胃泌酸调节素肽类似物
JP2024546799A (ja) Ｃｎｐコンジュゲートの有効用量
CN114867742A (zh) 胰高血糖素和glp-1受体的钉合内酰胺共激动剂
HK1191551A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
JP2015098464A (ja) Ｄｐｐ−４阻害剤の増強剤